Document is current

Any future updates will be listed below

Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial

Crossref DOI link: https://doi.org/10.1186/s43088-024-00487-9

Published Online: 2024-03-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark